Paper Details

  1. Home
  2. Paper Details

Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients.

Author: BellinviaM, BoneschiV, BrambillaL, GaianiF, ScoppioB, TourlakiA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Intralesional vincristine is effective and safe for treating classic Kaposi sarcoma nodular lesions. In a study of 151 patients, 98.7% had a response rate. The most common side effects were erythema and itching. This treatment is recommended as first-line therapy in initial stages and as support therapy in advanced stages.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Classic Kaposi sarcoma is a rare angioproliferative neoplasm with varying biological behaviour. Depending on the clinical stage, local or systemic therapy can be used. Vincristine has proven to be effective as systemic chemotherapy and in very few reports as intralesional treatment. OBJ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2133.2009.09601.x

データ提供：米国国立医学図書館（NLM）

Intralesional Vincristine: A Promising Treatment for Classic Kaposi Sarcoma

The field of [Kaposi sarcoma (KS)] treatment is constantly evolving, and researchers are seeking new and effective therapies for this complex disease. This prospective study investigates the efficacy and safety of [intralesional vincristine] as a first-line treatment for [nodular lesions] in [classic Kaposi sarcoma]. The authors found that [intralesional vincristine] demonstrated a high response rate and was generally well-tolerated, making it a promising therapeutic option for patients with this disease.

A New Oasis in the Desert of KS Treatment

This study offers a new avenue for managing [classic Kaposi sarcoma]. The findings suggest that [intralesional vincristine] could be a valuable tool in the fight against this disease, providing an effective and safe treatment option for patients with [nodular lesions]. The study's high response rate and manageable side effects highlight the potential of this approach for improving the lives of KS patients.

Hope and Healing in the Desert of KS

This study is a beacon of hope in the vast desert of [Kaposi sarcoma] research. The discovery of [intralesional vincristine] as a potential treatment option provides a new avenue for addressing this challenging disease. With continued research and development, we can strive for better and more effective treatments for KS patients.

Dr.Camel's Conclusion

Just like a camel navigating the vast and unforgiving desert, KS patients face a challenging journey. This study offers a promising oasis, providing a new and effective treatment option for those battling this disease. The results highlight the potential of intralesional vincristine as a powerful tool in the fight against KS, offering hope for a healthier and more fulfilling future for patients.

Date :
  1. Date Completed 2010-10-06
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

19995366

DOI: Digital Object Identifier

10.1111/j.1365-2133.2009.09601.x

Related Literature

Article Analysis
・Effective treatment of kaposi sarcoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.